Literature DB >> 29658302

Molecular Epidemiology of HIV-1 Virus in Puerto Rico: Novel Cases of HIV-1 Subtype C, D, and CRF-24BG.

Pablo López1, Omayra De Jesús1, Yasuhiro Yamamura1, Nayra Rodríguez1, Andrea Arias1, Raphael Sánchez1, Yadira Rodríguez1, Vivian Tamayo-Agrait2, Wilfredo Cuevas3, Vanessa Rivera-Amill1.   

Abstract

HIV-1 subtype B virus is the most prevalent subtype in Puerto Rico (PR), accounting for about 90% of infection in the island. Recently, other subtypes and circulating recombinant forms (CRFs), including F(12_BF), A (01_BF), and CRF-39 BF-like, have been identified. The purpose of this study is to assess the distribution of drug resistance mutations and subtypes in PR. A total of 846 nucleotide sequences from the period comprising 2013 through 2017 were obtained from our "HIV Genotyping" test file. Phylogenetic and molecular epidemiology analyses were performed to evaluate the evolutionary dynamics and prevalence of drug resistance mutations. According to our results, we detected a decrease in the prevalence of protease inhibitor, nucleoside reverse transcriptase inhibitor (NRTI), and non-NRTI (NNRTI) resistance mutations over time. In addition, we also detected recombinant forms and, for the first time, identified subtypes C, D, and CRF-24BG in PR. Recent studies suggest that non-subtypes B are associated with a high risk of treatment failure and disease progression. The constant monitoring of viral evolution and drug resistance mutation dynamics is important to establish appropriate efforts for controlling viral expansion.

Entities:  

Keywords:  HIV-1; HIV-1 subtypes; drug resistance mutations

Mesh:

Year:  2018        PMID: 29658302      PMCID: PMC5994676          DOI: 10.1089/AID.2017.0305

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  101 in total

1.  Recombination in HIV and the evolution of drug resistance: for better or for worse?

Authors:  Michael T Bretscher; Christian L Althaus; Viktor Müller; Sebastian Bonhoeffer
Journal:  Bioessays       Date:  2004-02       Impact factor: 4.345

2.  Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors.

Authors:  Stefano Menzo; Alessia Monachetti; Claudia Balotta; Stefano Corvasce; Stefano Rusconi; Stefania Paolucci; Fausto Baldanti; Patrizia Bagnarelli; Massimo Clementi
Journal:  AIDS       Date:  2003-03-28       Impact factor: 4.177

3.  Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling.

Authors:  H Vermeiren; E Van Craenenbroeck; P Alen; L Bacheler; G Picchio; P Lecocq
Journal:  J Virol Methods       Date:  2007-06-15       Impact factor: 2.014

Review 4.  Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications.

Authors:  L Buonaguro; M L Tornesello; F M Buonaguro
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

Review 5.  Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence.

Authors:  Jorge L Martínez-Cajas; Nitika Pant-Pai; Marina B Klein; Mark A Wainberg
Journal:  AIDS Rev       Date:  2008 Oct-Dec       Impact factor: 2.500

6.  The Decline in HIV-1 Drug Resistance in Heavily Antiretroviral-Experienced Patients Is Associated with Optimized Prescriptions in a Treatment Roll-Out Program in Mexico.

Authors:  Juan J Calva; Silvana Larrea; Marco A Tapia-Maltos; Mauricio Ostrosky-Frid; Carolina Lara; Pedro Aguilar-Salinas; Héctor Rivera; Juan P Ramírez
Journal:  AIDS Res Hum Retroviruses       Date:  2017-02-21       Impact factor: 2.205

7.  HIV Type 1 Integrase Natural Polymorphisms in Viral Variants Circulating in FSU Countries.

Authors:  Ilya Lapovok; Vita Laga; Elena Kazennova; Marina Bobkova
Journal:  Curr HIV Res       Date:  2017-11-23       Impact factor: 1.581

8.  Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors.

Authors:  P Richard Harrigan; Theresa Mo; Brian Wynhoven; Jennifer Hirsch; Zabrina Brumme; Paula McKenna; Theresa Pattery; Johan Vingerhoets; Lee T Bacheler
Journal:  AIDS       Date:  2005-03-24       Impact factor: 4.177

9.  Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen.

Authors:  Zoe Fox; Andrew Phillips; Cal Cohen; Jacquie Neuhaus; John Baxter; Sean Emery; Bernard Hirschel; Kathy Huppler Hullsiek; Christoph Stephan; Jens Lundgren
Journal:  AIDS       Date:  2008-11-12       Impact factor: 4.177

10.  HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir.

Authors:  K A Sutherland; J Ghosn; J Gregson; J L Mbisa; M L Chaix; I Cohen Codar; J F Delfraissy; C Delaugerre; R K Gupta
Journal:  J Antimicrob Chemother       Date:  2014-09-16       Impact factor: 5.790

View more
  1 in total

1.  Short Communication: Integrase Strand Transfer Inhibitors Drug Resistance Mutations in Puerto Rico HIV-Positive Individuals.

Authors:  Pablo López; Grissell Tirado; Andrea Arias; Raphael Sánchez; Elliott R Rodríguez-López; Vanessa Rivera-Amill
Journal:  Int J Environ Res Public Health       Date:  2021-03-08       Impact factor: 3.390

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.